Stem Cell–Derived Cells Enhance the Glucose Control of Patients With Type 1 Diabetes

Scientists boost the glucose control of patients with type 1 diabetes by implanting encapsulated stem cell-derived cells. The procedure will minimize insulin intake and benefit the health of many patients.

Type 1 diabetes (T1D) is a chronic disease that stops the pancreas from creating insulin. Patients with this condition would need a regular dose of insulin to prevent other health complications. A potential alternative to insulin is β cell replacement, which was used by scientists in this first-in-human trial of T1D patients.

Researchers conducted clinical studies to identify the effects of device-delivered stem cell–derived cells on the glucose of the T1D patients. After implanting the retrievable device, the patients developed a β cell mass with sufficient function to enhance glucose control. Their findings also indicate procedures for increasing the device's efficacy. The procedure may also eliminate the need for insulin dosage for over 50% of patients for more than 5 years.

For more information, read the journal article on Nature Biotechnology.

See https://www.isaaa.org/kc/cropbiotechupdate/article/default.asp?ID=20555